Can Erdafitinib treat liver cancer?

Erdafitinib has been primarily studied and approved for the treatment of advanced or metastatic urothelial carcinoma (UC), not liver cancer. The mechanism of action of erdafitinib is mainly to inhibit the growth of cancer cells by inhibiting the abnormal activation of fibroblast growth factor receptor (FGFR).

However, it should be noted that the fields of scientific research and drug application are constantly developing and evolving, and new studies and clinical trials may expand the indications of erdafitinib. If you are interested in whether erdafitinib has been or will be used to treat liver cancer, it is recommended to consult a professional doctor or consult the latest medical literature and clinical trial data to obtain the latest information.

Before considering any drug treatment, doctors typically evaluate a patient's specific situation, including factors such as medical history, tumor type, disease duration, and physical condition. At the same time, doctors may provide patients with the most appropriate treatment plan based on the latest clinical research and guidelines. Therefore, for the treatment of liver cancer, there may be other more suitable drugs or treatments, and the specific choice should be made by the doctor based on the patient's situation.

Erdafitinib is not currently available in the country, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, with a price of more than 20,000, and needs to be purchased through a Hong Kong pharmacy. The generic drugs are relatively cheaper, mainly the Laos version and the Bangladesh Yaopin International version, with a price of about 1,000 to 2,000, and the ingredients of the original drug and the generic drug are basically the same.